After standard preoperative treatment, surgery and postoperative comprehensive treatment for operable breast cancer patients, more than 90% of stage 1 patients can be cured, about 60% of stage 2 patients are cured, and about 40% of stage 3 patients are cured. Therefore, early diagnosis and treatment are very important, and the earlier the stage, the higher the cure rate. Stage 4 breast cancer refers to patients with metastasis at the first visit, and some post-operative breast cancer patients will have recurrent metastasis after a period of disease-free survival, which is the reason why post-operative patients need regular review as required, it is difficult to achieve cure for patients with recurrent metastasis, and the goal of treatment is to survive with tumor for a long time while improving the quality of life as much as possible. The purpose of regular review after early breast cancer surgery is to detect metastasis as early as possible and treat it in a timely manner, and regular review is required once every 3-6 months within 2 years after surgery, once every 6 months from 3-5 years after surgery, and once a year after 5 years after surgery. Many patients and their families, even non-oncology doctors, think that once metastasis occurs after breast cancer surgery, they will not live long, or they think that treatment after metastasis is very expensive and eventually they will be empty, so they just give up the treatment, which is a misconception. At present, with the combined application of various treatment methods, metastatic breast cancer has become a chronic disease with significantly longer survival period, and some patients can even fight for the rare chance to be cured again. The cost of some treatments is also not high, such as endocrine therapy for hormone receptor positive patients, various domestic chemotherapeutic drugs, even trastuzumab and lapatinib, which used to be expensive for HER2 positive patients, have significantly decreased after entering the national medical insurance negotiation catalog with price reduction and reimbursement, as well as the clinical studies of new drugs under continuous development have also played a pivotal role in prolonging patients’ survival All new drug clinical research protocols are approved by the State Drug Administration and reviewed by the hospital ethics department to maximize the protection of patients’ interests, on the one hand, they can receive potentially more effective treatment options earlier, on the other hand, all new drug clinical research drugs and tests are provided free of charge, which reduces the burden of long-term treatment for patients, and at the same time, the more patients participate in clinical research, the faster the new drug enters the clinic, and more patients will be treated. At the same time, the more patients participate in clinical research, the faster the new drugs will enter the clinic, and more patients will benefit from the new treatment methods. All of the above make long-term survival with tumor possible for recurrent metastatic breast cancer, and it would be a pity to give up without making efforts because of the lack of knowledge. For example, the following patient benefited from the clinical study of our new class 1.1 drug pyrrolizidine: Ms. Yang, female, 30 years old, came to our hospital for “postoperative lung metastasis from right breast cancer” on March 2017. I. Review past medical history and external treatment as follows: the patient underwent modified radical surgery for right breast cancer on 2013.10.18, postoperative pathology: invasive carcinoma, non-specific type, with intraductal carcinoma; LNM5/15, postoperative stage: pT2N2M0, immunohistochemistry (IHC): ER (-) PR (-) HER-2 (3+) Ki6740%. 2013.11- 2014.3 adjuvant chemotherapy: TCH x 6 cycles, 2014.3-2014.4 adjuvant radiotherapy, 2014.3-2014.11 adjuvant targeted therapy: trastuzumab (Herceptin) for a total of 1 year. 2015.6 pulmonary metastases found during routine review of chest CT (disease free survival 14 months), 2015.6.17-2015.7.22 radiotherapy for pulmonary nodules ( 60Gy/30f), the lesion shrank significantly, but increased in size six months later; 2016.3.9 External hospital performed “thoracoscopic left upper lung wedge resection”, postoperative pathology showed lung metastasis. Immunohistochemistry (IHC) of the lung lesion: ER (-) PR (-) HER-2 (3+) Ki6770%. Second, our hospital consultation: 2017.3 Chest CT showed a new lung lesion and was seen at our hospital. After admission, we reviewed the past medical history and met the enrollment screening criteria of the new drug pyrrolizidine phase IIIa clinical study, and after the patient’s informed consent, we screened as required and successfully enrolled, no other lesions were found, diagnosis: right breast cancer postoperative lung metastasis. 2017.3.22-2017.6 Disease progression after unblinding to the control group (placebo + capecitabine), i.e. capecitabine monotherapy, efficacy evaluation: disease progression (PD), time to disease progression (TTP) 2.5 months, 24.6.2017- re-informed consent, entered sequential pyrrolizidine monotherapy, efficacy evaluation partial remission (PR), currently still in disease remission continuing treatment. III.Summary HER-2-positive right breast cancer patient with postoperative lung metastasis, given second-line anti-HER2 targeted therapy after trastuzumab treatment, was enrolled in a phase IIIa clinical study of pyrrolitinib with double-blind randomization and unblinding after disease progression, and the patient was treated in the control group without targeted therapy (i.e., single-agent capecitabine group), and was subsequently treated with sequential single-agent The patient has been in remission for more than 18 months and continues to be treated, after 2 cycles of partial remission (PR). Long-term survival of patients with advanced breast cancer benefits from long-term effective treatment, and the more and longer the effective treatment, the longer the patient’s survival after metastasis, so active participation in clinical research is a very beneficial option for patients.